Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More

Cormorant Asset Management bought 5.8 million Erasca shares in the first quarter, an estimated $68.55 million position based on quarterly average pricing. The filing signals notable institutional accumulation and can be viewed as a constructive read-through for investor sentiment toward Erasca. The news is primarily flow-driven and is unlikely to have broad market impact.

Analysis

Cormorant Asset Management bought 5.8 million Erasca shares in the first quarter, an estimated $68.55 million position based on quarterly average pricing. The filing signals notable institutional accumulation and can be viewed as a constructive read-through for investor sentiment toward Erasca. The news is primarily flow-driven and is unlikely to have broad market impact.